These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. What do large scale studies of medication in schizophrenia add to our management strategies? Agius M; Davis A; Gilhooley M; Chapman S; Zaman R Psychiatr Danub; 2010 Jun; 22(2):323-8. PubMed ID: 20562774 [TBL] [Abstract][Full Text] [Related]
4. Benefit and risk assessment in drug development and utilization: a role for clinical pharmacology. Honig P Clin Pharmacol Ther; 2007 Aug; 82(2):109-12. PubMed ID: 17632530 [No Abstract] [Full Text] [Related]
5. Graphical approaches to the analysis of safety data from clinical trials. Amit O; Heiberger RM; Lane PW Pharm Stat; 2008; 7(1):20-35. PubMed ID: 17323410 [TBL] [Abstract][Full Text] [Related]
6. Test and power considerations for multiple endpoint analyses using sequentially rejective graphical procedures. Bretz F; Maurer W; Hommel G Stat Med; 2011 Jun; 30(13):1489-501. PubMed ID: 21290405 [TBL] [Abstract][Full Text] [Related]
7. The GRAIDS Trial: the development and evaluation of computer decision support for cancer genetic risk assessment in primary care. Emery J Ann Hum Biol; 2005; 32(2):218-27. PubMed ID: 16096220 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care. Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216 [TBL] [Abstract][Full Text] [Related]
9. The CATIE study and its implications for antipsychotic drug use. Janicak PG Essent Psychopharmacol; 2006; 7(1):53-63. PubMed ID: 16989293 [No Abstract] [Full Text] [Related]
10. [Priority for atypical antipsychotic drugs? Current studies clarify the issues]. Dose M Psychiatr Prax; 2007 Jan; 34(1):46-9. PubMed ID: 17265252 [No Abstract] [Full Text] [Related]
11. Strategies for the long-term treatment of schizophrenia: real-world lessons from the CATIE trial. Meyer JM J Clin Psychiatry; 2007; 68 Suppl 1():28-33. PubMed ID: 17286525 [TBL] [Abstract][Full Text] [Related]
13. Statistical aspects in comparative benefit-risk assessment: challenges and opportunities for pharmaceutical statisticians. Quartey G; Wang J Pharm Stat; 2012; 11(1):82-5. PubMed ID: 21997832 [TBL] [Abstract][Full Text] [Related]
14. How to manage in current treatment of schizophrenic patients. Loga S Psychiatr Danub; 2007 Dec; 19(4):359-61. PubMed ID: 18000489 [TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of treatment effects in schizophrenia. Stroup TS Am J Med; 2007 Apr; 120(4 Suppl 1):S26-31. PubMed ID: 17403379 [TBL] [Abstract][Full Text] [Related]
16. Meeting everyday challenges: antipsychotic therapy in the real world. Gorwood P Eur Neuropsychopharmacol; 2006 Sep; 16 Suppl 3():S156-62. PubMed ID: 16872807 [TBL] [Abstract][Full Text] [Related]
18. Introduction: evaluating the evidence: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and beyond. Nasrallah HA J Clin Psychiatry; 2007; 68 Suppl 1():3-4. PubMed ID: 17286521 [No Abstract] [Full Text] [Related]
19. Atypical antipsychotic drugs: current issues of safety and efficacy in the management of schizophrenia. Vohora D Curr Opin Investig Drugs; 2007 Jul; 8(7):531-8. PubMed ID: 17659473 [TBL] [Abstract][Full Text] [Related]
20. Pharmacoeconomic modelling in schizophrenia. Trap or support for decision makers? Hansen K; Lançon C; Toumi M Eur J Health Econ; 2006 Mar; 7(1):19-29. PubMed ID: 16528579 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]